For which mutations should patients diagnosed with metastatic CRC be tested?
The typical testing a few years ago was KRAS. That actually is now only part of the testing we should do for patients with metastatic colorectal cancer. Today, every patient should have an all RAS analysis, which includes KRAS and NRAS. The question of whether you add a BRAF analysis to that or not, it should not be routine, but I would suggest that it would be routine when you have capability to do it at your institution. BRAF would not inform you about EGFR, per se, but BRAF may lead you down a therapeutic path with, for example, triplet chemotherapy rather than a doublet chemotherapy plus bevacizumab.
Unresectable Colon Cancer: Case 2
52-year-old woman newly diagnosed with metastatic CRC and is genotyped as part of her initial work up.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More